Klickpfad

Regorafenib data at the 2012 ASCO-GI Congress

January 19 - 21, 2012
San Francisco, CA, U.S.

Results from the Phase III CORRECT study with regorafenib in patients with metastatic colorectal cancer were presented as a late breaking abstract in an oral abstract session on January 21 (2:30 PM - 4:00 PM Pacific Time) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA, U.S. On this occasion we held a conference call for investors and analysts.

Investor News Wednesday January 18, 2012

Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:

Positive Phase III Data on Bayer's Investigational Drug Regorafenib Show Significant Increase in Overall Survival

First presentation of data from CORRECT trial as "Late Breaking Abstract" at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI)

Monday, January 23, 2012 at approx. 12:30 p.m. CET (11:30 a.m. GMT): Investor Conference Call on Regorafenib

with
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Jörg Möller, Head of Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

On-demand audio recording of the presentation and discussion

Audio as MP3 and Podcast